methylhydroxynandrolone

Methylhydroxynandrolone (MOHN) is a synthetic anabolic–androgenic steroid (AAS) and a 17α-alkylated derivative of nandrolone (19-nortestosterone). It is orally active and was first described in the scientific literature in 1964. The compound was studied for potential use in the treatment of breast cancer but was never introduced for clinical use. Its mechanism of action involves agonism at the androgen receptor; as an anabolic steroid it promotes protein synthesis and muscle growth. Methylation at the C17 position confers oral bioavailability by preventing rapid hepatic metabolism. The drug re-emerged on the market as a "dietary supplement" around 2004 before being classified as a controlled substance due to its anabolic effects[1][2][3].

Other names

methylhydroxynandroloneMOHNMHN4-hydroxy-17alpha-methyl-19-nortestosteroneHMNT4,17β-dihydroxy-17α-methylestr-4-en-3-one